NEC OncoImmunity AS is a bioinformatics company offering proprietary machine-learning based software to address the key knowledge gaps in the prediction of bona fide immunogenic neoantigens for personalized cancer immunotherapy.
NEC OncoImmunity AS is dedicated to develop software solutions that facilitate effective patient selection for cancer immunotherapy, and identify optimal neoantigen targets for truly personalised cancer vaccines & cell therapies in a clinically actionable time-frame.
NEC OncoImmunity AS is a subsidiary of NEC Corporation, and is based in Oslo, Norway. The company was formerly named OncoImmunity AS. NEC Corporation, a global Japanese technology company, acquired OncoImmunity AS in July 2019, and hence the name changed to NEC OncoImmunity AS.
RADFORSK started to work with OncoImmunity AS in 2015 and were behind the first share issue in 2016. RADFORSK was deeply involved in the company’s development until the acquisition in 2019 as its biggest owner. Mr. Anders Tuv, Investment Director Radforsk, was Chairman of the Board until the acqusition, and was in charge of the sales process in relation to NEC Corporations.